Literature DB >> 23134263

Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance.

Paul T Bremer1, Kim D Janda.   

Abstract

We challenged the performance of our previous heroin vaccine with a similar vaccine containing a more hydrolytically stable hapten analogue and a Th1 adjuvant (CpG ODN). Our results indicate that the elements of our previous vaccine are essential for its anti-heroin potency, i.e., a chemically labile hapten and an exclusively Th2 humoral response elicited by alum. Such design elements are critical for producing next-generation heroin vaccines.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23134263      PMCID： PMC3527012          DOI： 10.1021/jm301262z

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  35 in total

1.  The economic costs of heroin addiction in the United States.

Authors:  T L Mark; G E Woody; T Juday; H D Kleber
Journal:  Drug Alcohol Depend       Date:  2001-01-01       Impact factor: 4.492

2.  Mechanism and function of a newly identified CpG DNA motif in human primary B cells.

Authors:  G Hartmann; A M Krieg
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

3.  Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.

Authors:  A Krug; S Rothenfusser; V Hornung; B Jahrsdörfer; S Blackwell; Z K Ballas; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

4.  Risk factors of HIV infection and needle sharing among injecting drug users in Ho Chi Minh City, Vietnam.

Authors:  N T Hien; L T Giang; P N Binh; W Devillé; E J van Ameijden; I Wolffers
Journal:  J Subst Abuse       Date:  2001

Review 5.  Extent of illicit drug use and dependence, and their contribution to the global burden of disease.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

6.  Drug harms in the UK: a multicriteria decision analysis.

Authors:  David J Nutt; Leslie A King; Lawrence D Phillips
Journal:  Lancet       Date:  2010-10-29       Impact factor: 79.321

7.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

8.  Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives.

Authors:  M P Wentland; W Duan; D J Cohen; J M Bidlack
Journal:  J Med Chem       Date:  2000-09-21       Impact factor: 7.446

9.  Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo.

Authors:  Jannike Mørch Andersen; Ase Ripel; Fernando Boix; Per Trygve Normann; Jørg Mørland
Journal:  J Pharmacol Exp Ther       Date:  2009-06-18       Impact factor: 4.030

10.  A second-generation vaccine protects against the psychoactive effects of cocaine.

Authors:  M R Carrera; J A Ashley; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205
View more
  21 in total

1.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

Review 2.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 3.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 4.  Adjuvants for vaccines to drugs of abuse and addiction.

Authors:  Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal:  Vaccine       Date:  2014-08-08       Impact factor: 3.641

5.  Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors:  Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal:  Mol Pharm       Date:  2018-02-19       Impact factor: 4.939

Review 6.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

7.  Lipid tucaresol as an adjuvant for methamphetamine vaccine development.

Authors:  K C Collins; J E Schlosburg; J W Lockner; P T Bremer; B A Ellis; K D Janda
Journal:  Chem Commun (Camb)       Date:  2014-04-21       Impact factor: 6.222

8.  Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs.

Authors:  Paul T Bremer; Atsushi Kimishima; Joel E Schlosburg; Bin Zhou; Karen C Collins; Kim D Janda
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

9.  Enhancement of a Heroin Vaccine through Hapten Deuteration.

Authors:  Tyson F Belz; Paul T Bremer; Bin Zhou; Beverly Ellis; Lisa M Eubanks; Kim D Janda
Journal:  J Am Chem Soc       Date:  2020-07-27       Impact factor: 15.419

10.  Synthesis and immunological effects of heroin vaccines.

Authors:  Fuying Li; Kejun Cheng; Joshua F G Antoline; Malliga R Iyer; Gary R Matyas; Oscar B Torres; Rashmi Jalah; Zoltan Beck; Carl R Alving; Damon A Parrish; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Org Biomol Chem       Date:  2014-10-07       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.